All In Biotech

Drug Trial Radar · NCT04608110

A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome

A Phase 1, Multi-center, Open-label, Uncontrolled, Dose-escalation Study to Evaluate the Pharmacokinetics of ASTX030 in Patients With Myelodysplastic Syndrome (MDS)

Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

59

Planned (sponsor's estimate)

Start

Oct 30, 2020

Primary completion

Dec 2027

Study completion Jan 2028

Sponsor

Lead sponsor
Taiho Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 29, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

\[Tolerability Assessment Part\] The purpose is to identify the doses of the oral azacitidine(AZA) formulations and cedazuridine (CED) tablets which achieve a total AUC for AZA comparable to that for AZA injection at 75 mg/m2. \[Expansion Assessment Part\] The purpose is to compare the total AUC for AZA after administration of ASTX030 with that after administration of AZA injection at 75 mg/m2.

Conditions

  • Myelodysplastic Syndrome (MDS)

Interventions

  • ASTX030 (AZA + CED)Drug

    In Cycle 1 (28 days per cycle), subcutaneous (SC) AZA will be administered on Day 1, followed by oral AZA formulations and CED tablets on Days 2-7. In Cycle 2 and onward, oral AZA formulations and CED tablets will be administered on Day 1-7.

  • ASTX030 (AZA + CED)Drug

    In Cycle 1 (28 days per cycle), ASTX030 will be administered on Days 1-7. In Cycle 2, SC AZA will be administered on Days 1-7 according to a crossover design. From Cycle 3 onward, ASTX030 will be administered on Days 1-7.

  • ASTX030 (AZA + CED)Drug

    In Cycle 1 (28 days per cycle), SC AZA will be administered on Days 1-7. In Cycle 2, ASTX030 will be administered on Days 1-7 according to a crossover design. From Cycle 3 onward, ASTX030 will be administered on Days 1-7.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. [Tolerability Assessment Part] AUC ratio of AZA after administration of oral AZA formulations in combination with CED tablets compared with SC administration of AZA injection.Time frame: Up to 1 month
  2. [Expansion Assessment Part] AUC ratio of AZA after administration of ASTX030 compared with SC administration of AZA injectionTime frame: Up to 2month

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Nippon Medical School Hospital

    Bunkyō City, Japan · Recruiting

  • Fukushima Medical University Hospital

    Fukushima, Japan · Recruiting

  • Saitama Medical University Hospital

    Iruma, Japan · Recruiting

  • University Hospital, Kyoto Prefectural University of Medicine

    Kyoto, Japan · Recruiting

  • Nagasaki University Hospital

    Nagasaki, Japan · Recruiting

  • Osaka City General Hospital

    Osaka, Japan · Recruiting

  • Kindai University Hospital

    Sakai, Japan · Recruiting

  • NTT Medical Center Tokyo

    Shinagawa-Ku, Japan · Recruiting

  • Tokyo Medical University Hospital

    Shinjuku-Ku, Japan · Recruiting

  • Yamagata University Hospital

    Yamagata, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.